Kanishk Steel (513456)
Asset PlayScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹27.65 |
| Market Cap | ₹78.99 Cr |
| P/E Ratio | 41.32 |
| ROCE | 5.52% |
| ROE | 3.91% |
| Dividend Yield | 0% |
| Profit Growth | -75.72% |
| Debt/Equity | — |
| Sales Growth | 9.31% |
| 52-Week Range | ₹40.15 — ₹66.95 |
| Sector | Industrial Products |
| Book Value | ₹35.63 |
Strengths
- Trades at ₹27.65, roughly 22% below book value of ₹35.63, with P/B at 0.78
- Sales growth is positive at 9.31% despite the tough steel environment
- Latest quarter is still profitable: ₹96 Cr sales and ₹2 Cr net profit
- ROCE of 5.52% shows assets are generating some return, not fully idle
- Small market cap of ₹79 Cr may leave room for asset unlock or control premium
Concerns
- Profit growth has collapsed by 75.72%, and the P/E of 41.32 is based on depressed earnings
- ROE of only 3.91% and zero dividend yield mean poor returns for shareholders
- Piotroski F-Score of 4/9 points to weak financial fundamentals
- Price is below the stated 52-week low of ₹40.15, suggesting downward momentum or potential data inconsistency; promoter and debt data are also unavailable
AI Analysis
When I look at Kanishk Steel, I see a small iron and steel business selling for less than its stated assets. At ₹27.65, the market cap is only ₹79 crore, while book value per share is ₹35.63. That is a P/B of 0.78, a Graham-style discount. But a low price relative to book is not enough. This is a commodity business with no obvious moat, and the numbers confirm it. Return on equity is just 3.91%, and return on capital employed is only 5.52%. Profits have collapsed by 75.72%, leaving the stock with an elevated P/E of 41.32. That is not a growth multiple; it is a warning that earnings are depressed. Sales grew 9.31%, and the latest quarter shows ₹96 crore in revenue and ₹2 crore in net profit, so the company is still functioning. But there is no dividend yield to compensate while I wait, and the Piotroski score of 4 out of 9 suggests weak financial health. The price is even below the stated 52-week range, which makes me cautious about data quality and momentum. I would treat this not as a quality compounder but as a cyclical asset play. The margin of safety depends on the real value of the assets and management's ability to improve returns. Without a reliable catalyst, the discount to book can persist or get deeper. I need evidence of higher ROCE, stable margins, and better capital allocation before committing. For a retail investor, this is a small watch-list situation, not a core holding. In Buffett's language, it is a cigar butt—possibly one or two puffs left, but not a wonderful business. I'd demand a clear plan for unlocking value, or buy only with a much wider safety margin than this.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer